Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the childrens cancer group

James R. Anderson, R. Derek T. Jenkin, John F. Wilson, Carl R. Kjeldsberg, Richard Sposto, Robert R. Chilcote, Peter F. Coccia, Philip R. Exelby, Stuart Siegel, Anna T. Meadows, G. Denman Hammond

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Purpose: We analyzed the long-term results of a Childrens Cancer Group (CCG) randomized study comparing cyclophosphamide, vincristine, methotrexate, and prednisone (COMP) versus LSA2L2 as treatment for childhood non-Hodgkin's lymphoma. The initial results were previously reported (N Engl J Med 308:559, 1983). Patients and Methods: A total of 429 patients are reported here, 68 with localized disease and 361 with disseminated disease. The distribution of disseminated-disease patients by histologie type was 164 lymphoblastic, 60 large-cell, and 137 undifferentiated lymphomas. Median follow-up duration of surviving patients is 8 years. Results: Event-free survival (EPS) of patients with localized disease was 84% at 5 years. No differences were seen between the two treatment regimens. Results for patients with disseminated disease was dependent on histologic subtype: patients with lymphoblastic lymphoma did better when treated with LSA2L2 (5-year EFS of 64% v 35% for COMP); COMP produced better results for patients with undifferentiated lymphoma (5-year EFS of 50% v 29% for LSA2L2). Results for large-cell lymphoma patients were similar (5-year EFS of 52% for COMP v 43% for LSA2L2). Five percent of patients died of treatment-related complications while on therapy (primarily infections). Only four deaths without progression have been observed off-therapy (two from restrictive lung disease, one from an acute asthma attack, one from colon cancer). Patient survival rates after recurrence were poor. Conclusion: Treatment success can be expected in 84% of pediatric patients with localized non-Hodgkin's lymphoma. For patients with disseminated disease, treatment success can be expected in 64% of those with lymphoblastic and 50% of those with undifferentiated or large-cell disease. To date, late adverse events are rare.

Original languageEnglish (US)
Pages (from-to)1024-1032
Number of pages9
JournalJournal of Clinical Oncology
Volume11
Issue number6
DOIs
StatePublished - Jan 1 1993

Fingerprint

Vincristine
Prednisone
Methotrexate
Non-Hodgkin's Lymphoma
Cyclophosphamide
Neoplasms
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Colonic Neoplasms
Lung Diseases
Disease-Free Survival
Lymphoma
Asthma
Survival Rate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma : A report of CCG-551 from the childrens cancer group. / Anderson, James R.; Jenkin, R. Derek T.; Wilson, John F.; Kjeldsberg, Carl R.; Sposto, Richard; Chilcote, Robert R.; Coccia, Peter F.; Exelby, Philip R.; Siegel, Stuart; Meadows, Anna T.; Hammond, G. Denman.

In: Journal of Clinical Oncology, Vol. 11, No. 6, 01.01.1993, p. 1024-1032.

Research output: Contribution to journalArticle

Anderson, JR, Jenkin, RDT, Wilson, JF, Kjeldsberg, CR, Sposto, R, Chilcote, RR, Coccia, PF, Exelby, PR, Siegel, S, Meadows, AT & Hammond, GD 1993, 'Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the childrens cancer group', Journal of Clinical Oncology, vol. 11, no. 6, pp. 1024-1032. https://doi.org/10.1200/JCO.1993.11.6.1024
Anderson, James R. ; Jenkin, R. Derek T. ; Wilson, John F. ; Kjeldsberg, Carl R. ; Sposto, Richard ; Chilcote, Robert R. ; Coccia, Peter F. ; Exelby, Philip R. ; Siegel, Stuart ; Meadows, Anna T. ; Hammond, G. Denman. / Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma : A report of CCG-551 from the childrens cancer group. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 6. pp. 1024-1032.
@article{8418d184ae604818af34b703a2c4b0a5,
title = "Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the childrens cancer group",
abstract = "Purpose: We analyzed the long-term results of a Childrens Cancer Group (CCG) randomized study comparing cyclophosphamide, vincristine, methotrexate, and prednisone (COMP) versus LSA2L2 as treatment for childhood non-Hodgkin's lymphoma. The initial results were previously reported (N Engl J Med 308:559, 1983). Patients and Methods: A total of 429 patients are reported here, 68 with localized disease and 361 with disseminated disease. The distribution of disseminated-disease patients by histologie type was 164 lymphoblastic, 60 large-cell, and 137 undifferentiated lymphomas. Median follow-up duration of surviving patients is 8 years. Results: Event-free survival (EPS) of patients with localized disease was 84{\%} at 5 years. No differences were seen between the two treatment regimens. Results for patients with disseminated disease was dependent on histologic subtype: patients with lymphoblastic lymphoma did better when treated with LSA2L2 (5-year EFS of 64{\%} v 35{\%} for COMP); COMP produced better results for patients with undifferentiated lymphoma (5-year EFS of 50{\%} v 29{\%} for LSA2L2). Results for large-cell lymphoma patients were similar (5-year EFS of 52{\%} for COMP v 43{\%} for LSA2L2). Five percent of patients died of treatment-related complications while on therapy (primarily infections). Only four deaths without progression have been observed off-therapy (two from restrictive lung disease, one from an acute asthma attack, one from colon cancer). Patient survival rates after recurrence were poor. Conclusion: Treatment success can be expected in 84{\%} of pediatric patients with localized non-Hodgkin's lymphoma. For patients with disseminated disease, treatment success can be expected in 64{\%} of those with lymphoblastic and 50{\%} of those with undifferentiated or large-cell disease. To date, late adverse events are rare.",
author = "Anderson, {James R.} and Jenkin, {R. Derek T.} and Wilson, {John F.} and Kjeldsberg, {Carl R.} and Richard Sposto and Chilcote, {Robert R.} and Coccia, {Peter F.} and Exelby, {Philip R.} and Stuart Siegel and Meadows, {Anna T.} and Hammond, {G. Denman}",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.6.1024",
language = "English (US)",
volume = "11",
pages = "1024--1032",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma

T2 - A report of CCG-551 from the childrens cancer group

AU - Anderson, James R.

AU - Jenkin, R. Derek T.

AU - Wilson, John F.

AU - Kjeldsberg, Carl R.

AU - Sposto, Richard

AU - Chilcote, Robert R.

AU - Coccia, Peter F.

AU - Exelby, Philip R.

AU - Siegel, Stuart

AU - Meadows, Anna T.

AU - Hammond, G. Denman

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: We analyzed the long-term results of a Childrens Cancer Group (CCG) randomized study comparing cyclophosphamide, vincristine, methotrexate, and prednisone (COMP) versus LSA2L2 as treatment for childhood non-Hodgkin's lymphoma. The initial results were previously reported (N Engl J Med 308:559, 1983). Patients and Methods: A total of 429 patients are reported here, 68 with localized disease and 361 with disseminated disease. The distribution of disseminated-disease patients by histologie type was 164 lymphoblastic, 60 large-cell, and 137 undifferentiated lymphomas. Median follow-up duration of surviving patients is 8 years. Results: Event-free survival (EPS) of patients with localized disease was 84% at 5 years. No differences were seen between the two treatment regimens. Results for patients with disseminated disease was dependent on histologic subtype: patients with lymphoblastic lymphoma did better when treated with LSA2L2 (5-year EFS of 64% v 35% for COMP); COMP produced better results for patients with undifferentiated lymphoma (5-year EFS of 50% v 29% for LSA2L2). Results for large-cell lymphoma patients were similar (5-year EFS of 52% for COMP v 43% for LSA2L2). Five percent of patients died of treatment-related complications while on therapy (primarily infections). Only four deaths without progression have been observed off-therapy (two from restrictive lung disease, one from an acute asthma attack, one from colon cancer). Patient survival rates after recurrence were poor. Conclusion: Treatment success can be expected in 84% of pediatric patients with localized non-Hodgkin's lymphoma. For patients with disseminated disease, treatment success can be expected in 64% of those with lymphoblastic and 50% of those with undifferentiated or large-cell disease. To date, late adverse events are rare.

AB - Purpose: We analyzed the long-term results of a Childrens Cancer Group (CCG) randomized study comparing cyclophosphamide, vincristine, methotrexate, and prednisone (COMP) versus LSA2L2 as treatment for childhood non-Hodgkin's lymphoma. The initial results were previously reported (N Engl J Med 308:559, 1983). Patients and Methods: A total of 429 patients are reported here, 68 with localized disease and 361 with disseminated disease. The distribution of disseminated-disease patients by histologie type was 164 lymphoblastic, 60 large-cell, and 137 undifferentiated lymphomas. Median follow-up duration of surviving patients is 8 years. Results: Event-free survival (EPS) of patients with localized disease was 84% at 5 years. No differences were seen between the two treatment regimens. Results for patients with disseminated disease was dependent on histologic subtype: patients with lymphoblastic lymphoma did better when treated with LSA2L2 (5-year EFS of 64% v 35% for COMP); COMP produced better results for patients with undifferentiated lymphoma (5-year EFS of 50% v 29% for LSA2L2). Results for large-cell lymphoma patients were similar (5-year EFS of 52% for COMP v 43% for LSA2L2). Five percent of patients died of treatment-related complications while on therapy (primarily infections). Only four deaths without progression have been observed off-therapy (two from restrictive lung disease, one from an acute asthma attack, one from colon cancer). Patient survival rates after recurrence were poor. Conclusion: Treatment success can be expected in 84% of pediatric patients with localized non-Hodgkin's lymphoma. For patients with disseminated disease, treatment success can be expected in 64% of those with lymphoblastic and 50% of those with undifferentiated or large-cell disease. To date, late adverse events are rare.

UR - http://www.scopus.com/inward/record.url?scp=0027294591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027294591&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.6.1024

DO - 10.1200/JCO.1993.11.6.1024

M3 - Article

C2 - 8501488

AN - SCOPUS:0027294591

VL - 11

SP - 1024

EP - 1032

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -